A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has identified a potential biomarker of Parkinson's disease progression.
Local people affected by Parkinson’s are invited to a free event in Salford to help learn more about the condition and the ...
Parkinson's disease is a debilitating neurological ... appear years before an official diagnosis is made. This pioneering UK study delved into the neurodegenerative disorder within a diverse ...
GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...
Parkinson UK’s Taunton and Mid Somerset branch has issued an appeal for volunteers to help run the day-to-day operations of the branch, including organising activities, managing the group’s finances ...
Parkinson's is a progressive neurological condition, meaning that it causes problems in the brain and gets worse over time. It affects around 153,000 people in the UK. People with Parkinson's ...
Nov. 12, 2024 — Researchers have identified a potential biomarker of Parkinson's disease progression. According to the new study, patients with a slow progression of ... Oct. 8, 2024 ...
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
Large study reveals surprising links between common antibiotics, antifungal treatments, and Parkinson’s risk ... information from a United Kingdom (UK)- wide network of electronic health ...
Parkinson’s disease (PD) is a progressive disorder of the nervous system. It primarily affects movement but can also lead to other symptoms, significantly impacting quality of life over time.
Oct. 18, 2024 -- The FDA has approved a new injectable treatment for adults with advanced Parkinson’s disease called Vyalev (also known as Produodopa). This new option is designed to help people ...
BioVie (BIVI) announced that the upcoming PD-202 A Double-Blind, Randomized, Placebo-controlled, Study of Bezisterim in Subjects with Early Parkinson’s Disease is now fully funded. Favorable ...